{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'treatment interruption with no further recurrence or sequelae. Table 7 in', \"the apalutamide Investigator's Brochure lists all Phase II treatment-\", 'related Grades 3 AEs.', 'Apalutamide was recently approved by the FDA for use in men', 'with non-metastatic CRPC on the basis of Phase III data showing that it', 'significantly prolonged the time to development of metastatic disease39 In', 'the pivotal Phase III study, patients with a PSA doubling time <10 months', 'were randomized 2:1 between apalutamide or placebo. Men in the', 'apalutamide group had a median metastasis-free survival of 40.5 months', 'vs. 16.2 months in the placebo group (HR = 0.28; 95% CI 0.23 to 0.35;', 'P<0.001). Several additional studies evaluating apalutamide are ongoing,', 'including a Phase I trial evaluating it in combination with abiraterone', 'acetate in a mCRPC population [clinicaltrials.gov NCT01792687].', '1.3. Active Surveillance', 'While watchful waiting is primarily focused on avoiding treatment in those with', 'advanced prostate cancer and a minimal life expectancy, active surveillance is geared', 'towards individualizing management in those with favorable risk disease who are', 'otherwise fit for local therapy - the intent being to not sacrifice overall cure rates while', 'minimizing', 'overtreatment.\u00b9 11 Those individuals felt most appropriate for this strategy', 'have traditionally had low to very low-risk localized prostate cancer, usually as defined', \"by the criteria proposed by Epstein or D'Amico; however, several cohorts now allow\", 'men with favorable-intermediate risk disease (i.e., low-volume Gleason 3+4', 'disease)', '14,40-42 By focusing on those with favorable risk disease, active surveillance has', 'been able to achieve comparable survival rates compared to those receiving immediate', 'treatment while allowing approximately 45% to 70% of men to avoid local therapy', '(Table 2).', '13,14 Furthermore, given that upward of 45% of men may qualify for active', 'surveillance (i.e., have at least low risk disease), if management of patients per this', 'paradigm becomes more widely accepted, the number of men avoiding unnecessary', 'local therapy could reach nearly 50,000 per year in the United States alone. 43,44', '15', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Inclusion Criteria', 'Number', 'Any', 'meeting', 'given', 'Number', 'Prostate', 'Total', 'all', 'Median', 'Median', 'Total', 'core', 'receiving', 'Cancer', 'number', 'inclusion', 'age', 'follow-up', 'positive', 'positivity', 'local therapy', 'os', 'Specific', 'Center', 'enrolled', 'criteria (%)', '(years)', '(months)', 'Gleason', 'PSA criteria', 'cT', 'cores', '(%)', '(%)', '(%)', 'os (%)', 'Johns', '769', '633 (82)', '66', '32', 'Gleason <3+3', 'PSA density <0.15', '1', '<2', '<50%', '255 (33.2)', '98', '100', 'Hopkins11', 'ng/ml/ml', 'University of', '230', '230 (100)', '64', '32', 'Gleason <6', 'PSA <10 ng/ml', '<2', '<2', '<20%', '32 (14)', '100', '100', 'Miami45', 'University of', '640', '376 (59)', '62', '47', 'Gleason <3+3', 'PSA <10 ng/ml', '<2', '<33%', '<50%', 'Low-risk', '97', '100', 'California San', '(n=376):', 'Francisco46', '104 (28)', 'Intermediate', 'risk (n=90):', '27 (28)', 'University of', '993', '993 (100)', '68', '77', 'Gleason <6', 'Before year 2000:', '-', '267 (27)', '85', '98.5', 'Toronto14', 'Gleason <3+4', 'Men <70 years-old:', '(select', 'PSA <10 ng/ml', 'patients only)', 'Men >70 years-old:', 'PSA <15 ng/ml', 'After year 2000:', 'PSA <10 ng/ml', 'Life expectancy <10', 'years/significant', 'comorbidities: PSA', '10-20 ng/ml', 'Memorial-', '238', '238 (100)', '64', '22', '<3+3', 'PSA <10 ng/ml', '<2a', '<3', '<50%', '-', '-', 'Sloan', 'Kettering47', 'able 2: Key North American active surveillance cohorts. Abbreviations: OS, overall survival; cT, clinical tumor stage.', '16', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}